Cannabis Law Report

MAY 19, 2022

This is Numinus’ first psilocybin-assisted therapy treatment outside of ongoing clinical trials, and among the first to use of this regulatory mechanism through Health Canada’s Special Access Program (“SAP”), which was amended January 5 th , 2022 to include access to psychedelic compounds on a case-by-case basis.

Therapy 52

Therapy Treatment Clinical Trials Access 52

NORML

APRIL 30, 2020

According to state-registry records, “Chronic pain is currently and historically the most common qualifying condition reported by medical cannabis patients (67.5 ” This finding is hardly a surprise, as cannabis is well-established to mitigate pain in clinical models, particularly in patients with neuropathy.

Chronic Pain 339

Chronic Pain Clinical Trials Data Patients 339

Cannabis Law Report

DECEMBER 15, 2021

A number of clinical trials have been investigating the potential of psychedelics in mental health treatment. “I agree with the committee that the preliminary findings from clinical trials — although still in early phases — evaluated by the panel are promising,” the decision’s author said.

Clinical Trials 52

Clinical Trials Conditions Supply Chain Environment 52

NORML

JANUARY 31, 2019

“These men and women put on the uniform to defend this nation’s freedoms and it is the height of hypocrisy for the federal government to deny them rights afforded to the millions of other Americans who reside in states where access to medical cannabis is legally recognized.”

Clinical Trials 188

Clinical Trials Chronic Pain Data Treatment 188

MMJ Recs

APRIL 1, 2024

CBD, one of the many cannabinoids found in the cannabis plant, has been garnering attention for its promising effects on various health conditions. From its anti-inflammatory properties to its ability to alleviate pain, CBD shows promise in addressing various health conditions.

CBD 52

CBD Clinical Trials Chronic Pain Epilepsy 52

Veriheal

MARCH 2, 2024

In December of 2023, the country recently made a new move towards reform that could stimulate the cannabidiol (CBD) industry and provide many patients, such as those with epilepsy , with access to potentially life-changing medical treatments. and Europe to treat severe epilepsy, as well as other medical conditions.

Legalization 91

Legalization Epilepsy Clinical Trials THC 91

Veriheal

MARCH 20, 2023

While decriminalization decreases the negative impact of legal issues, it does not provide accessible, safe, and regulated psilocybin for those seeking treatment. Andy Smith (D) stated that he is “working on a bill forming a psychedelic medicine task force so Minnesotans can access these life-affirming treatments. Missouri Rep.

Clinical Trials 98

Clinical Trials Therapy Decriminalization Treatment 98

MMJ Recs

DECEMBER 17, 2023

Enacted in 2015, the program was designed to provide a narrow avenue for patients suffering from qualifying conditions to access low-THC cannabis under the supervision of qualified healthcare professionals. Physician’s Prescription: Patients must obtain a prescription from a qualified physician registered with the TCUP.

Law 52

Law Dispensary Clinical Trials Programs 52

Veriheal

FEBRUARY 9, 2023

A fascinating new clinical trial demonstrates how this psychedelic compound could make people significantly more comfortable while undergoing MRIs or similar procedures. All imaging and behavioral data will be accessible to the public after the study is complete. What Is an MRI?

Clinical Trials 91

Clinical Trials Research and Development Data Collective 91

Cannabis Law Report

DECEMBER 5, 2021

The Multidisciplinary Association for Psychedelic Studies (MAPS) and Vine Ventures have announced the creation of a novel, social impact Special Purpose Vehicle (SPV), called the Regenerative Financing Vine (RFV), that will infuse $70 million into patient access infrastructure and research for MDMA-assisted therapy for PTSD.

Therapy 52

Therapy Access Research and Development Clinical Trials 52

Cannabis Law Report

JUNE 24, 2022

Scutari’s proposed “Psilocybin Behavioral Health Access and Services Act” represents a bold development in the psychedelics reform movement that’s rapidly spread in state legislatures and through citizen-led initiatives throughout the country in recent years. Full story at.

Clinical Trials 52

Clinical Trials Legalization Research and Development Therapy 52

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. 2022 Active FDA Clinical Trials and State-Regulated Systems. Active FDA Regulated Clinical Trials*. On March 5, 2019, the U.S. Schedule I.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

SEPTEMBER 8, 2021

Key Transaction Details: The Valens Company, a leading Canadian manufacturer of cannabis products, has entered into a long-term partnership with Epsilon, for exclusive access to the Epsilon’s GMP Manufacturing Facility in Southport , Queensland Australia (the “ Southport Facility ‘).

Access 97

Access Research and Development Medicine THC 97

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. Publication of this process establishes “prior art,” contributing to MAPS’ patient access strategy by making intellectual property public .

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

AUGUST 17, 2021

Orphan drug designation provides certain benefits, including market exclusivity upon regulatory approval, if received, exemption of FDA application fees and tax credits for qualified clinical trials. The live webcast can be accessed here and on the investor page of Marinus’ website. Conference Call and Webcast Details.

Pharmaceutical 98

Pharmaceutical Clinical Trials Treatment Patients 98

The Joint Blog

FEBRUARY 11, 2022

With more corners of the world coming around and legalizing the use of CBD for research and treatment of various conditions, a greater understanding of its potential for good is just now becoming apparent. This includes clinical trials on humans. Does this mean that CBD is a cure for a virus? And on grander scales.

Clinical Trials 49

Clinical Trials CBD Conditions Data 49

Cannabis Law Report

OCTOBER 5, 2021

Systematic literature review of the therapeutic value, benefits and risks of MDMA and psilocybin for the treatment of mental health conditions. The Independent Expert Panel was established to undertake a systematic literature review of the roles of MDMA and psilocybin for the treatment of mental health conditions. 30 September 2021.

Treatment 52

Treatment Conditions Medicine Clinical Trials 52

Cannabis Law Report

MAY 10, 2022

Of the 248,000 scripts approved for Australians since inception of national medicinal cannabis scheme in 2016, many related to conditions for which the drug has limited evidence of efficacy, a new University of Sydney study shows. Since the beginning of the program, medicinal cannabis has been prescribed for over 140 conditions.

Medicine 52

Medicine Clinical Trials Sleep Data 52

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. European Regulatory Lead Executive Summary.

Clinical Trials 52

Clinical Trials Research and Development Therapy Compliance 52

Veriheal

MAY 3, 2022

a necessary question to address as medical marijuana becomes more accessible. The outcomes and measures used throughout the trial included changes in CUD symptoms; anxiety and depressive symptoms; pain severity; and insomnia symptoms. Clinical Trial Sample Size. Daily Cannabis Use as a Disqualifier.

Research and Development 95

Research and Development Clinical Trials Consumption Patients 95

SpeedWeed

SEPTEMBER 17, 2021

Data collected from MAPS-sponsored Phase 3 clinical trials suggests that MDMA-assisted therapy appears promising in the treatment of TBI. The millions of people afflicted with PTSD may soon have access to MDMA therapy, and we believe the millions suffering from TBI may experience similar relief in the future.”.

Clinical Trials 53

Clinical Trials Research and Development Therapy Treatment 53

Canna Law Blog

NOVEMBER 27, 2021

Notwithstanding its dubious distinction as a Schedule I drug, DMT increasingly is the subject of study for its potential efficacy in treating a wide array of mental-health conditions including depression, anxiety, and PTSD. regulators to launch a clinical program to study the use of DMT for the treatment of stroke-related dysfunction.

Therapy 87

Therapy Clinical Trials DEA Microdosing 87

Cannabis Law Report

SEPTEMBER 22, 2021

Access to Canopy Growth’s cannabinoid library including 335 derivatives and 14 patent families. Accelerated timelines to clinical trials and expansion of drug development pipeline. Phase 1 clinical trials are scheduled for Q3 2022 with Phase 2 trials expected in Q2 2023.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Cannabinoids 52

Cannabis Law Report

OCTOBER 4, 2021

A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Accordingly, it cannot be prescribed by a physician and it is not legally accessible to those who might benefit from it as a therapeutic treatment.

Therapy 52

Therapy Patients Law Clinical Trials 52

The Cannigma

APRIL 12, 2023

Sleep is not often the focus of clinical trials on cannabis; rather it is often a secondary outcome. This direct access to consumers allows MoreBetter to conduct informal studies, collecting data from a set of participants with a selected product over a set amount of time. Has CBN been proven to help with sleep?

Sleep 133

Sleep Data Tincture Research and Development 133

Cannabis Law Report

MAY 10, 2022

More than half of all prescriptions for medicinal cannabis in Australia are written by doctors in Queensland, with prescriptions often given for conditions there is little evidence medicinal cannabis can treat, new research reveals. We are aware of clinical trials in that space, but not strong evidence.”.

Medicine 52

Medicine Clinical Trials Data Sleep 52

Cannabis Law Report

MAY 19, 2022

After a psilocybin treatment,(it’s like) you’re still in your car, in traffic, but you have the windows up; the air conditioning is on and it’s quiet. Before January, people could only access psychedelic-assisted psychotherapy through clinical trials or medical exemptions. It’s just you and the music.”

Therapy 52

Therapy Patients Treatment Clinical Trials 52

Cannabis Law Report

AUGUST 14, 2021

Cann Group CEO Peter Crock said of the products: “Satipharm CBD capsules were one of the first medicinal cannabis products available to approved patients in Australia (under the Special Access Scheme) and have been successfully used in a variety of medical conditions since 2017.

CBD 105

CBD Clinical Trials Programs Food 105

Cannabis Law Report

JUNE 21, 2021

Most of the data came from five states that list these indications as qualifying conditions for the use of medical cannabis. But if that doctor has access to information from 40,000 patients it’s a different story. RYAH Smart inhalers are being used in a huge clinical trial based in the UK.

Data 105

Data Clinical Trials Research and Development Indica 105

MMJ Recs

NOVEMBER 20, 2023

Both THC and CBD have demonstrated analgesic properties, making them valuable for managing chronic pain conditions such as arthritis, fibromyalgia, and cancer-related pain. Epilepsy Management: CBD, in particular, has emerged as an effective treatment for epilepsy, especially in individuals with rare and severe forms of the condition.

Cannabinoids 98

Cannabinoids Epilepsy Treatment Marijuana 98

The Cannigma

FEBRUARY 2, 2021

Of these consumers, over half said the drug had a beneficial clinical effect on their condition. As medicinal cannabis treatments are now legal in many parts of the world, naturally, there is a growing interest in whether the products can treat neurological conditions like Parkinson’s disease. Still, research is ongoing.

Patients 87

Patients Clinical Trials Research and Development Treatment 87

The Cannigma

AUGUST 26, 2021

The country legalized medical cannabis in 2016, but patients in the country have long criticized the program as too restrictive, and access to cannabis-based medicines remains behind that of many other legal cannabis jurisdictions. This also means that the TGA has not accessed these medicines for their safety, quality, or effectiveness.

Legalization 52

Legalization Access Medicine Clinical Trials 52

NORML

JANUARY 18, 2019

House lawmakers introduced The Medical Cannabis Research Act of 2019 (HR 601), to facilitate federally-approved clinical trials involving cannabis. At the state level, patients in Ohio and Oklahoma now have access to medical cannabis, as sales began in both states this week. Additionally, a bipartisan coalition of U.S.

Legislation 159

Legislation Decriminalization Access Therapy 159

Cannabis Law Report

NOVEMBER 22, 2019

. “As MMJ International Holdings continues to advance to its clinical trials, a specialty pharmaceutical solutions company will be supporting MMJ with the FDA, DEA required development API and specialized liquid encapsulation solutions,” said Elio Mariani, PhD, EVP of Research & Development. 561-627-9455. 917-562-9610.

DEA 66

DEA Clinical Trials THC Research and Development 66

Cannabis Law Report

NOVEMBER 19, 2021

It has been designated a Breakthrough Therapy by the FDA and the results of our pivotal Phase 3 clinical trial were published in Nature Medicine or profiled on the front page of The New York Times. MAPS PBC strives to establish a supportive, equitable and accessible work environment. Key Responsibilities. Position Requirements.

Research and Development 52

Research and Development Clinical Trials Therapy Pharmaceutical 52

Kind Meds (Cannabis Education Blog)

NOVEMBER 18, 2020

It seems like the medical research community remains largely divided on the issue, with some insisting that cannabis use contributes to mental health condition diagnoses while others suggesting that people with mental health conditions are inherently drawn to cannabis use.

Treatment 111

Treatment Conditions CBD Clinical Trials 111

Cannabis Law Report

AUGUST 2, 2021

Radicle ACES will use validated, standardized health indices to gather health outcome data from a diverse population across a variety of ethnicities, age groups, geographies, behavioral habits, and pre-existing health conditions. We are delighted to have Lord Jones involved in the Radicle Sciences’ ACES study.

CBD 105

CBD Data Sleep Clinical Trials 105